(Q56741838)

1

0 references

Tonsok Kim

2

0 references

Masatoshi Hori

4

0 references

Hiroaki Nagano

5

0 references

Yasuhiro Nakaya

6

0 references

Takahiro Tsuboyama

7

0 references

Atsushi Nakamoto

8

0 references

Mitsuaki Tatsumi

9

0 references

Seishi Kumano

10

0 references

Masahiro Okada

11

0 references

Manabu Takamura

12

0 references

Kenichi Wakasa

13

0 references

Noriyuki Tomiyama

14

0 references

Takamichi Murakami

https://scigraph.springernature.com/pub.10.1007/s00330-011-2316-y

15

0 references

language of work or name

English

0 references

publication date

April 2012

0 references

published in

European Radiology

0 references

volume

22

0 references

issue

4

0 references

page(s)

845-54

0 references

exact match

0 references

cites work

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Resection of hepatocellular carcinoma without preoperative tumor biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Safety of gadolinium-DTPA: Extended clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Consensus report of the 2nd International Forum for Liver MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatoce

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Efficacy of double-arterial phase gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced liver magnetic resonance imaging compared with double-arterial phase multi-detector row helical computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Double phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Hepatocellular Carcinoma: Role of Unenhanced and Delayed Phase Multi–Detector Row Helical CT in Patients with Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Hypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Free-response methodology: alternate analysis and a new observer-performance experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

"Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2316-Y

Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects.

21 January 2018

1 reference

12 December 2020

Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow

1 reference

12 December 2020

Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy

1 reference

12 December 2020

Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography

1 reference

12 December 2020

MR-guided liver tumor ablation employing open high-field 1.0T MRI for image-guided brachytherapy

1 reference

12 December 2020

Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions

1 reference

12 December 2020

Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases

1 reference

12 December 2020

Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging

1 reference

12 December 2020

Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats

1 reference

12 December 2020

Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats

1 reference

12 December 2020

Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence

1 reference

12 December 2020

Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA

1 reference

12 December 2020

A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI.

1 reference

12 December 2020

Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations

1 reference

12 December 2020

The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging

1 reference

12 December 2020